Acadia Pharmaceuticals Inc
NASDAQ:ACAD 4:00:00 PM EDT
| Market Cap (Intraday) | 2.81B |
| Current PE | N/A |
| Forward PE | 25.88 |
| 2yr Forward PE | 13.34 |
| 10-Day MA | $17.57 |
| 50-Day MA | $21.51 |
| 200-Day MA | $24.82 |
Acadia Pharmaceuticals Inc Stock, NASDAQ:ACAD
12830 El Camino Real, Suite 400, San Diego, California 92130-3331
United States of America
Phone: +1.858.558.2871
Number of Employees: 598
Description
ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.